Panacea Biotec Of India To Buy Stake In PharmAthene Of U.S.
This article was originally published in PharmAsia News
India's Panacea Biotec plans to buy a large stake in PharmAthene, a U.S. biodefense company that makes products to counter biological and chemical threats. Panacea intends to buy 14.5 percent of the U.S. firm for $13.1 million through its Kelisia Holdings, a wholly owned subsidiary. The deal also gives Panacea the option of buying enough shares to give it practically a 20 percent stake in the American firm. (Click here for more
You may also be interested in...
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
LifeSignals plans to soon launch a biosensor patch to consumers to help them monitor for potential symptoms of COVID-19.
FDA and FTC's latest warning letters include the first firm marketing CBD products linked with bogus COVID-19 claims. Latest warnings also mark the first the agencies submitted based completely or nearly entirely on regulatory violations found in businesses social media postings.